22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ULTRAGENYX PHARMACEUTICAL INC. › 2024-2025

ULTRAGENYX PHARMACEUTICAL INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed May 19, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 350Asset managers, any item
  • 1,977Fund votes
  • May 15, 2025Meeting date

Results at a glance

Meeting of May 15, 2025: 5 items on ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed May 19, 2025: 2 approved · 3 passed (calculated).

Dissent

Significant dissent: 1 say-on-pay vote (67.9% support).

Notable dissent: 1 director (14.0% against); 1 other board item (33.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Nantahala Capital (13F, 2.3%, as of September 30, 2026)

Explore ULTRAGENYX PHARMACEUTICAL INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ULTRAGENYX PHARMACEUTICAL INC.

These tallies are ULTRAGENYX PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 19, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ULTRAGENYX PHARMACEUTICAL INC. — official shareholder meeting results, meeting held May 15, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Matthew K. Fust 69,816,485---- 11,374,8835,318,239 86%Passed (calculated)—
Elect Director: Amrit Ray, M.D. 77,323,215---- 3,868,1535,318,239 95%Passed (calculated)—
Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan. The votes on Proposal 2 were 54,269,11426,890,35531,899 --5,318,239 67%Approved—
Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal yea 84,295,9412,188,72224,894 ---- 97%Approved—
4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as described 55,098,06026,074,20719,101 --5,318,239 68%Passed (calculated)—

Source: ULTRAGENYX PHARMACEUTICAL INC., Form 8-K, filed with the SEC on May 19, 2025 — read the filing on EDGAR.

How asset managers voted at the ULTRAGENYX PHARMACEUTICAL INC. 2024-2025 meeting

350 asset managers disclosed a vote on at least one ULTRAGENYX PHARMACEUTICAL INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Amrit Ray, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 77,323,215WITHHELD: 3,868,153
Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: Nominees: Amrit Ray, M.D.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Amrit Ray, M.D.”): 77,323,215 for, 3,868,153 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 100 asset managers below reported 31,761,945 for, 1,217,208 withheld, 57,789 abstained.

FOR
FOR: 31,761,945ABSTAIN: 57,789WITHHOLD: 1,217,208
Largest asset managers voting on “Nominees: Amrit Ray, M.D.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,411,5370 10For
T. Rowe Price2,407,5370 034,900For
BlackRock2,349,2120 00For
Fidelity2,171,4830 00For
Federated Hermes2,049,8000 00For
Legg Mason1,319,8880 00For
State Street1,175,7120 00For
Invesco959,4770 00For
ACAP Strategic Fund826,6980 00For
TOUCHSTONE FUNDS GROUP TRUST801,7960 00For
Charles Schwab589,5580 00For
TIAA458,8100 00For
Aberdeen441,1690 00For
MFS441,0900 00For
Putnam346,8350 00For
AllianceBernstein00 0345,774Withhold
Loomis Sayles326,7890 00For
AB DISCOVERY GROWTH FUND, INC.00 0316,731Withhold
Goldman Sachs285,9430 00For
John Hancock253,4200 00For
BNY Mellon245,9070 00For
Advantage Advisers Xanthus Fund, L.L.C.241,2210 00For
Principal00 0181,774Withhold
DRIEHAUS MUTUAL FUNDS177,8930 00For
Jackson National171,5070 00For

Showing the 25 largest of 100 asset managers. All 100 are in the interactive database (link above).

Elect Director: Matthew K. Fust

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%WITHHELD
FOR: 69,816,485WITHHELD: 11,374,883
Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: Nominees: Matthew K. Fust

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Matthew K. Fust”): 69,816,485 for, 11,374,883 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 100 asset managers below reported 28,706,489 for, 4,272,662 withheld, 57,790 abstained.

FOR
FOR: 28,706,489ABSTAIN: 57,790WITHHOLD: 4,272,662
Largest asset managers voting on “Nominees: Matthew K. Fust” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,411,5360 20For
T. Rowe Price2,407,5370 034,900For
BlackRock2,349,2120 00For
Fidelity2,171,4830 00For
Federated Hermes2,049,8000 00For
Legg Mason1,319,8880 00For
State Street3,3580 01,172,354Withhold
Invesco00 0959,477Withhold
ACAP Strategic Fund826,6980 00For
TOUCHSTONE FUNDS GROUP TRUST801,7960 00For
Charles Schwab589,5580 00For
TIAA458,8100 00For
Aberdeen441,1690 00For
MFS00 0441,090Withhold
Putnam346,8350 00For
AllianceBernstein00 0345,774Withhold
Loomis Sayles326,7890 00For
AB DISCOVERY GROWTH FUND, INC.00 0316,731Withhold
Goldman Sachs00 0285,943Withhold
John Hancock253,4200 00For
BNY Mellon245,9070 00For
Advantage Advisers Xanthus Fund, L.L.C.241,2210 00For
Principal00 0181,774Withhold
DRIEHAUS MUTUAL FUNDS177,8930 00For
Jackson National171,5070 00For

Showing the 25 largest of 100 asset managers. All 100 are in the interactive database (link above).

Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023…

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

67% Approved · of votes cast

FOR 67%AGAINST
FOR: 54,269,114AGAINST: 26,890,355
Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: Approval of the Second Amended and Restated 2023 Incentive Plan.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 2: Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 54,269,114 for, 26,890,355 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 – Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 98 asset managers voting on “Approval of the Second Amended and Restated 2023 Incentive Plan.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,411,5317 00For
T. Rowe Price2,407,53734,900 00For
BlackRock2,349,2120 00For
Fidelity1,573,548597,935 00Mixed
Federated Hermes2,049,8000 00For
Legg Mason1,319,8880 00For
State Street2,2561,173,456 00Against
Invesco959,4770 00For
ACAP Strategic Fund0826,698 00Against
TOUCHSTONE FUNDS GROUP TRUST801,7960 00For
Charles Schwab589,5580 00For
TIAA0458,810 00Against
Aberdeen0441,169 00Against
MFS0441,090 00Against
Putnam0346,835 00Against
AllianceBernstein345,7740 00For
Loomis Sayles326,7890 00For
AB DISCOVERY GROWTH FUND, INC.316,7310 00For
Goldman Sachs0285,943 00Against
John Hancock26,489226,931 00Mixed
BNY Mellon0245,907 00Against
Advantage Advisers Xanthus Fund, L.L.C.0241,221 00Against
Principal181,7740 00For
DRIEHAUS MUTUAL FUNDS0177,893 00Against
Jackson National0171,507 00Against

Fund voting reports, all 98 managers: 26,064,450 for, 6,921,569 against, 13,308 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 2 asset managers voting on “Approval of the Second Amended and Restated 2023 Incentive Plan.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
First Light Asset Management, LLC608,4560 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC0782 00Against

Institutional-manager reports, all 2 managers: 608,456 for, 782 against.

Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 11 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%AGAINST
FOR: 55,098,060AGAINST: 26,074,207

Prior year: 73.9% for (June 18, 2024 meeting) ▼ 6.1 pts

Details: description as filed, official tally, votes by 349 asset managers

Description as filed by funds: Advisory (non-binding) vote to approve the compensation of our named executive officers.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its ”): 55,098,060 for, 26,074,207 against, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 100 asset managers voting on “Advisory (non-binding) vote to approve the compensation of our named executive officers.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,669,450742,088 00Mixed
T. Rowe Price2,407,53734,900 00For
BlackRock2,349,2120 00For
Fidelity2,171,4830 00For
Federated Hermes2,049,8000 00For
Legg Mason01,319,888 00Against
State Street1,173,4532,259 00For
Invesco959,4770 00For
ACAP Strategic Fund0826,698 00Against
TOUCHSTONE FUNDS GROUP TRUST801,7960 00For
Charles Schwab589,5580 00For
TIAA0458,810 00Against
Aberdeen0441,169 00Against
MFS0441,090 00Against
Putnam346,8350 00For
AllianceBernstein0345,774 00Against
Loomis Sayles326,7890 00For
AB DISCOVERY GROWTH FUND, INC.0316,731 00Against
Goldman Sachs0285,943 00Against
John Hancock118,618134,802 00Mixed
BNY Mellon5,516240,391 00Against
Advantage Advisers Xanthus Fund, L.L.C.0241,221 00Against
Principal112,20669,568 00Mixed
DRIEHAUS MUTUAL FUNDS0177,893 00Against
Jackson National147,84023,667 00Mixed

Fund voting reports, all 100 managers: 25,653,387 for, 7,384,946 against, 13,308 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 278 asset managers voting on “Advisory (non-binding) vote to approve the compensation of our named executive officers.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price3,173,15454,975 00For
BlackRock2,996,67228,305 00For
SANDS CAPITAL MANAGEMENT, LLC2,854,8910 00For
State Street2,402,21343,322 00For
Clearbridge Investments, LLC02,230,833 00Against
Wellington2,073,2960 00For
Federated Hermes2,049,8040 00For
SUVRETTA CAPITAL MANAGEMENT, LLC02,001,935 00Against
ADAGE CAPITAL PARTNERS GP, L.L.C.1,983,6820 00For
RTW INVESTMENTS, LP1,707,4020 00For
GEODE CAPITAL MANAGEMENT, LLC1,631,6930 00For
Rock Springs Capital Management LP1,371,0910 00For
Deep Track Capital, LP1,350,0000 00For
PICTET ASSET MANAGEMENT SA01,245,699 00Against
Point7201,203,546 00Against
AllianceBernstein01,139,433 00Against
Invesco1,088,2170 00For
BNP Paribas Asset Management Holding S.A.01,068,334 00Against
Alyeska Investment Group, L.P.0899,044 00Against
Two Sigma0881,261 00Against
Frazier Life Sciences Management, L.P.830,9150 00For
Avoro Capital Advisors LLC830,0000 00For
Candriam S.C.A.0728,017 00Against
ALKEON CAPITAL MANAGEMENT LLC0654,668 00Against
First Light Asset Management, LLC608,4560 00For

Institutional-manager reports, all 278 managers: 34,853,645 for, 19,365,194 against, 1,380 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 84,295,941AGAINST: 2,188,722

Prior year: 98.3% for (June 18, 2024 meeting) ▼ 0.8 pts

Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 84,295,941 for, 2,188,722 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 100 asset managers below reported 33,011,107 for, 12,527 against, 13,308 abstained.

FOR
FOR: 33,011,107AGAINST: 12,527ABSTAIN: 13,308
Largest asset managers voting on “Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for th” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard11,411,5380 00For
T. Rowe Price2,442,4370 00For
BlackRock2,349,2120 00For
Fidelity2,171,4830 00For
Federated Hermes2,049,8000 00For
Legg Mason1,319,8880 00For
State Street1,175,63379 00For
Invesco959,4770 00For
ACAP Strategic Fund826,6980 00For
TOUCHSTONE FUNDS GROUP TRUST801,7960 00For
Charles Schwab589,5580 00For
TIAA458,8100 00For
Aberdeen441,1690 00For
MFS441,0900 00For
Putnam346,8350 00For
AllianceBernstein345,7740 00For
Loomis Sayles326,7890 00For
AB DISCOVERY GROWTH FUND, INC.316,7310 00For
Goldman Sachs285,9430 00For
John Hancock253,4200 00For
BNY Mellon245,9070 00For
Advantage Advisers Xanthus Fund, L.L.C.241,2210 00For
Principal181,7740 00For
DRIEHAUS MUTUAL FUNDS177,8930 00For
Jackson National171,5070 00For

Showing the 25 largest of 100 asset managers. All 100 are in the interactive database (link above).

Largest ULTRAGENYX PHARMACEUTICAL INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 93,903,785 shares outstanding at the time of that meeting.

Fund voting reports: top ULTRAGENYX PHARMACEUTICAL INC. shareholders by shares voted on “Advisory (non-binding) vote to approve the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 12.15%
2T. Rowe Price 2.60%
3BlackRock 2.50%
4Fidelity 2.31%
5Federated Hermes 2.18%
6Legg Mason 1.41%
7State Street 1.25%
8Invesco 1.02%
9ACAP Strategic Fund 0.88%
10TOUCHSTONE FUNDS GROUP TRUST 0.85%
Institutional-manager reports: top ULTRAGENYX PHARMACEUTICAL INC. shareholders by shares voted on “Advisory (non-binding) vote to approve the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1T. Rowe Price 3.44%
2BlackRock 3.22%
3SANDS CAPITAL MANAGEMENT, LLC 3.04%
4State Street 2.60%
5Clearbridge Investments, LLC 2.38%
6Wellington 2.21%
7Federated Hermes 2.18%
8SUVRETTA CAPITAL MANAGEMENT, LLC 2.13%
9ADAGE CAPITAL PARTNERS GP, L.L.C. 2.11%
10RTW INVESTMENTS, LP 1.82%

Reported ULTRAGENYX PHARMACEUTICAL INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ULTRAGENYX PHARMACEUTICAL INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group9,996,226 10.65%Form 13F, quarter ended March 31, 2025
BlackRock6,158,266 6.56%Form 13F, quarter ended March 31, 2025
FMR LLC3,347,890 3.57%Schedule 13G, filed February 5, 2026
Emil D. Kakkis, M.D., Ph.D.3,293,909 3.51%Proxy statement (DEF 14A), table as of March 7, 2025
T. Rowe Price3,218,942 3.43%Form 13F, quarter ended March 31, 2025
State Street2,618,490 2.79%Form 13F, quarter ended March 31, 2025
Wellington Management2,449,498 2.61%Form 13F, quarter ended March 31, 2025
Geode Capital1,646,537 1.75%Form 13F, quarter ended March 31, 2025
Invesco1,213,282 1.29%Form 13F, quarter ended March 31, 2025
Point72976,052 1.04%Form 13F, quarter ended March 31, 2025

Percentages above are of 93,903,785 shares outstanding, as reported by ULTRAGENYX PHARMACEUTICAL INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ULTRAGENYX PHARMACEUTICAL INC.'s shareholder meeting held May 15, 2025, in the 2024-2025 proxy season, 350 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,977 separate fund positions. On the most widely held item on that ballot — Advisory (non-binding) vote to approve the compensation of our named executive officers. — FOR was 68% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ULTRAGENYX PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 19, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ULTRAGENYX PHARMACEUTICAL INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ULTRAGENYX PHARMACEUTICAL INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “ULTRAGENYX PHARMACEUTICAL (RARE) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ultragenyx-pharmaceutical-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.